ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Tumor Infiltrating Lymphocytes LM103

Also written as “LM103”, “LM103 TILs Injection” and “Autologous tumor infiltrating lymphocytes (TILs)”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung, led by Suzhou BlueHorse Therapeutics.

Drug pageAutologous Tumor Infiltrating Lymphocytes LM103: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 16, 20257 company-led studies, 7 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou BlueHorse Therapeutics77 open or runningphase 2since Dec 16, 2025May 5, 2022Dec 31, 2027phase 2 · NCT07310784

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2022First study: phase 1 study in MelanomaFirst studyNCT05366478 · 15 planned · China
  2. Jun 26, 2023Early phase 1 study in Solid TumorNCT05941936 · 5 planned · China
  3. Jul 12, 20232 early phase 1 studies in Solid TumorNCT05971589, NCT05971576
  4. Nov 15, 2024Early phase 1 study in Solid CancerNCT06697665 · 10 planned · China
  5. Dec 16, 2025Phase 2 study in Advanced MelanomaPhase 2 reachedNCT07310784 · 92 planned · China
  6. Feb 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07444437 · 45 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07444437
  2. Dec 31, 2027Primary completion: phase 2 study in Advanced MelanomaNCT07310784

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07444437Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 31, 202745
NCT07310784Advanced Melanoma · China2RecruitingDec 31, 202792
NCT06697665Solid Cancer · ChinaEarly 1RecruitingJan 202610
NCT05971589Solid TumorEarly 1Not yet recruitingApr 20265
NCT05971576Solid TumorEarly 1Not yet recruitingApr 202620
NCT05941936Solid Tumor · ChinaEarly 1RecruitingFeb 20255
NCT05366478Melanoma · China1RecruitingMay 30, 202415

How it is read

Names in the registry

  • “LM103”, 4 entries
  • “LM103 TILs Injection”, 2 entries
  • “Autologous tumor infiltrating lymphocytes (TILs)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.